Amicus Therapeutics
FOLDApprovedAmicus Therapeutics is a pioneer in the development of novel treatments for rare metabolic diseases, particularly lysosomal storage disorders. The company has successfully commercialized Galafold for Fabry disease and is advancing a next-generation pipeline that includes enzyme replacement therapies (ERTs) like Pombiliti + Opfolda for Pompe disease and gene therapies for conditions such as CLN6 Batten disease. Their strategy combines scientific innovation in protein engineering and gene therapy with a global commercial footprint to address significant unmet medical needs.
FOLD · Stock Price
Historical price data
AI Company Overview
Amicus Therapeutics is a pioneer in the development of novel treatments for rare metabolic diseases, particularly lysosomal storage disorders. The company has successfully commercialized Galafold for Fabry disease and is advancing a next-generation pipeline that includes enzyme replacement therapies (ERTs) like Pombiliti + Opfolda for Pompe disease and gene therapies for conditions such as CLN6 Batten disease. Their strategy combines scientific innovation in protein engineering and gene therapy with a global commercial footprint to address significant unmet medical needs.
Technology Platform
Two core platforms: 1) Pharmacological chaperone technology for oral small molecule therapies that stabilize mutant enzymes, and 2) Next-generation enzyme replacement and gene therapy platforms utilizing engineered proteins and AAV vectors for targeted delivery.
Pipeline Snapshot
4343 drugs in pipeline, 14 in Phase 3
| Drug | Indication | Stage |
|---|---|---|
| migalastat hydrochloride + Placebo | Fabry Disease | Phase 3 |
| Migalastat HCl 20 mg | Fabry Disease | Phase 3 |
| AT2221 + ATB200 | Pompe Disease (Late-onset) | Phase 3 |
| Cipaglucosidase alfa + Miglustat | Glycogen Storage Disease Type II Infantile Onset | Phase 3 |
| migalastat HCl 150 mg | Fabry Disease | Phase 3 |
Funding History
4Total raised: $375M
FDA Approved Drugs
3Opportunities
Risk Factors
Competitive Landscape
Primary competitors are large pharma companies like Sanofi and Takeda in Fabry and Pompe disease. Amicus differentiates through its oral therapy for Fabry and its next-generation enzyme engineering for Pompe, aiming for superior efficacy and patient convenience.
Company Info
Trading
Contact
Therapeutic Areas
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile